P. LEOMBRUNI, F. AMIANTO, V. MONDELLI, G. ABBATE DAGA, D. DOSIO, A. PIERÒ, S. FASSINO - Vol. 9, December 2003, Issue 4
Testo Bibliografia Summary Indice
Trattamento farmacologico dei disturbi del comportamento
alimentare
Pharmacological treatment of eating disorders
1 Andersen AE. Eating disorders in males. In: Bronwell K, Fairburn CG, eds. Eating disorder and obesity: a comprehensive handbook. New York: Guilford Press 1995:177-87.
2 American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-IV. 4th ed. Washington (DC): American Psychiatric Association 1994.
3 Walsh BT, Devlin MJ. Eating diosrders: a progress and problems. Science 1998;280:1387-90.
4 Fassino S, Abbate Daga G, Amianto, Leombruni P, Boggio S, Rovera GG. Temperament and character profile of eating disorders: a controlled study with the Temperament and Character Inventory. Int J Eat Disord 2002;4:412-25.
5 Sullivan PF. Mortality in anorexia nervosa. Am J Psychiatry 1995;152:1073-4.
6 Fassino S, Abbate Daga G, Amianto F, Leombruni P, Fornas B, Garzaro L, et al. Outcome Predictors in Anorectic Patients after 6 months of Multimodal Treatment. Psychoter Psychosom 2001;70:201-8.
7 Dally P, Sargant W. A new treatment of anorexia nervosa. BMJ 1960;1:1770-3.
8 Dally P, Sargant W. Treatment and outcome of anorexia nervosa. BMJ 1966;2:793-5.
9 Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. Acta Psychiatr Scand 1982;66:445-50.
10 Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled study with sulpiride. Br J Psychiatry 1984;144:288-92.
11 Jensen VS, Mejlhede A. Anorexia nervosa: treatment with olanzapine. Br J Psychiatry 2000:177-87.
12 La Via MC, Gray N, Kaye WH. Case reports of olanzapine treatment of anorexia nervosa. Int J Eat Disord 2000;27:363-6.
13 Powers PS, Santana CA, Bannon YS. Olanzapine in the treatment of anorexia nervosa: an open label trial. Int J Eat Disord 2002;2:146-54.
14 Gross HA, Ebert MH, Faden VB, Goldberg SC, Nee Le, Kaye WH. A double-blind controlled trial of lithium carbonate in primary anorexia nervosa. J Clin Psychopharmacol 1981;1:376-81.
15 Lacey JH, Crisp AH. Hunger, food intake and weight: the impact of clomipramine on a refeeding anorexia nervosa population. Postgrad Med J 1980;56(Suppl 1):79-85.
16 Biederman J, Herzog DB, Rivinus TM, Harper GP, Ferber RA, Rosenbaum JF, et al. Amitriptyline in the treatment of anorexia nervosa: a double-blind, placebo-controlled study. J Clin Psychopharmacol 1985;5:10-6.
17 Halmi KA, Eckert ED, LaDu TJ, Cohen J. Anorexia nervosa: treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry 1986;43:177-81.
18 Wilens TE, Biederman J, Baldessarini RJ, Geller B, Schleifer D, Spencer TJ, et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 1996;35:1491-501.
19 Ferguson JM. Treatment of an anorexia nervosa patient with fluoxetine. Am J Psychiatry 1987;144:1239.
20 Gwirtsman HE, Guze BH, Yager J, Gainsley B. Fluoxetine treatment of anorexia nervosa: an open clinical trial. J Clin Psychiatry 1990;51:378-82.
21 Attia E, Haiman C, Walsh BT, Flater SR. Does fluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry 1998;155:548-51.
22 Kaye WH, Nagata T, Weltzin TE, Hsu LK, Sokol MS, McConaha C, et al. Double-blind placebo-controlled administration of fluoxetine in restricting and restricting-purging-type anorexia nervosa. Biol Psychiatry 2001;49:644-52.
23 Ferguson PC, La Via MC, Crossan PJ, Kaye WH. Are Serotonin Selective Reuptake Inhibitors effective in underweight anorexia nervosa? Int J Eat Disord 1999;1:11-7.
24 Santoanastaso P, Friederici S, Favaro A. Sertraline in the treatment of restricting anorexia nervosa: an open controlled trial. J Child Adolesc Psychopharmacol 2001;2:143-50.
25 Fassino S, Leombruni P, Abbate Daga G, Brustolin A, Migliaretti G, Cavallo F, et al. Efficacy of citalopram in anorexia nervosa: a pilot study. Eur Neuropsychopharmacol 2002;5:453-9.
26 Vigersky RA, Loriaux DL. The effect of cyproheptadine in anorexia nervosa: a double-blind trial. In: Vigersky RA, ed. Anorexia Nervosa. New York: Raven Press 1977:349-56.
27 Goldberg SC, Halmi KA, Eckert ED, Casper RC, Davis JM. Cyproheptadine in anorexia nervosa. Br J Psychiatry 1979;134:67-70.
28 Gross HA, Ebert MH, Faden VB, Goldberf SC, Kaye WH, Caine ED, et al. A double-blind trial of delta9-tetrahydrocannabinol in primary anorexia nervosa. J Clin Psychopharmacol 1983;3:165-71.
29 Bryce-Smith D, Simpson RI. Case of anorexia nervosa responding to zinc sulphate. Lancet 1984;2:350.
30 Esca SA, Brenner W, Mach K, Gschnait F. Kwashiorkor-like zinc deficiency syndrome in anorexia nervosa. Acta Derm Venereol 1979;59:361-4.
31 Thomsen K. Zinc, liver cirrhosis and anorexia nervosa. Acta Derm Venereol 1978;58:283.
32 Safai-Kutti S. Oral zinc supplementation in anorexia nervosa. Acta Psychiatr Scand 1990;361:S14-7.
33 Katz RL, Keen CL, Litt IF, Hurley LS, Kellams-Harrison KM, Glader L. Zinc deficiency in anorexia nervosa. J Adolesc Health Care 1987;8:400-6.
34 Birmingham CL, Goldner EM, Bakan R. Controlled trial of zinc supplementation in anorexia nervosa. Int J Eat Disord 1994;15:251-5.
35 Lask B, Fosson A, Rolfe U, Thomas S. Zinc deficiency and childhood-onset anorexia nervosa. J Clin Psychiatry 1993;54:63-6.
36 Hsu LKG. Epidemiology of the eating disorders. Psychiatr Clin North Am 1996;19:681-700.
37 Stein DM. The prevalence of bulimia: A review of the empirical research. J Nutr Educ 1991;23:205-13.
38 Mitchell JE, Raymond N, Specker S. A review of the controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa. Int J Eat Disord 1993;14:229-47.
39 Walsh BT, Devlin MJ. The pharmacologic treatment of eating disorders. In: Shaffer D ed. Psychiatr Clin North Am 1992;15:149-60.
40 Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa: a multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry 1992;49:139-47.
41 Romano SJ, Halmi KA, Sarkar NP, Koke SC, Lee JS. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry 2002;159:96-102.
42 Calandra C, Gulino V, Inserra L, Giuffrida A. The use of citalopram in an integrated approach to the treatment of eating disorders: an open study. Eat Weight Disord 1999;4:207-10.
43 El-Giamal N, de Zwaan M, Bailer U, Lennkh C, Schussler P, Strand A, et al. Reboxetine in the treatment of bulimia nervosa: a report of seven cases. Int Clin Psychopharmacol 2000;6:351-6.
44 Carruba MO, Cuzzolaro M, Riva L, Bosello O, Liberti S, Castra R, et al. Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial. Int Clin Psychopharmacol 2001;1:27-32.
45 Wermuth BM, Davis KL, Hollister LE, Stunkard AJ. Phenytoin treatment of the binge-eating syndrome. Am J Psychiatry 1977;134:1249-53.
46 Kaplan AS, Garfinkel PE, Darby PL, Garner DM. Carbamazepine in the treatment of bulimia. Am J Psychiatry 1983;140:1225-6.
47 Knable M. Topiramate for bulimia nervosa in epilepsy. Am J Psychiatry 2001;158:322-3.
48 Hadigane CM, Walsh BT, Devlin MJ, LaChaussee JL, Kissileff HR. Behavioral assessment of satiety in bulimia nervosa. Appetite 1992;18:233-41.
49 Faris PL, Kim SW, Meller WH, Goodale RL, Hofbauer RD, Oakman SA, et al. Effect of ondansetron, a 5-HT3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds. Pain 1998;77:297-303.
50 Faris PL, Kim SW, Meller WH, Goodale RL, Oakam SA, Hofabauer RD, et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 2000;355:792-7.
51 Blouin AG, Blouin JH, Perez EL, Bushnik T, Zuro C, Mulder E. Treatment of bulimia with fenfluramina and desipramine. J Clin Psychopharmacol 1988;8:261-9.
52 Krahn D, Mitchell J. Use of L-tryptophan in treating bulimia. Am J Psychiatry 1985;142:1130.
53 Fahy TA, Eisler I, Russel GFM. A placebo-controlled trial of d-fenfluramine in bulimia nervosa. Br J Psychiatry 1993;162:597-603.
54 Russell GFM, Checkley SA, Feldman J, Eisler I. A controlled trial of d-fenfluramine in bulimia nervosa. Clin Neuropharm 1988;11(Suppl 1):S146-59.
55 Alger SA, Schwalberg MD, Bigaouette JM, Michalek AV, Howard LJ. Effect of a tricyclic antidepressant and opiate antagonist on binge eating in normoweight bulimic and obese, binge-eating subjects. Am J Clin Nutr 1991;53:865-71.
56 Mitchell JE, Christenson G, Jennings J, Huber M, Thomas B, Pomeroy C, et al. A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia. J Clin Psychopharmacol 1989;9:94-7.
57 Hsu LKG, Clement L, Santhouse R, Ju ESY. Treatment of bulimia nervosa with lithium carbonate. A controlled study. J Neur Trans 1991;179:351-5.
58 Wilson GT, Fairburn CG, Agras WS. Cognitive-behavioral therapy for bulimia nervosa. In: Garner DM, Garfinkel PE, eds. Handbook of treatment for eating disorders. New York: Guilford Press 1997:67-93.
59 Mitchell JE, Pyle RL, Eckert ED, Hatsukami D, Pomeroy C, Zimmerman R. A comparison study of antidepressant and structured group psychotherapy in the treatment of bulimia nervosa. Arch Gen Psychiatry 1990;47:149-57.
60 Fichter MM, Leibl K, Rief W, Brunner E, Schmidt-Auberger S, Engel RR. Fluoxetine versus placebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry 1991;24:1-7.
61 Agras WS, Arnow B, Schneidr JA, Telch CF, Raeburn SD, Bruce B, et al. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. Am J Psychiatry 1992;49:82-7.
62 Leitenberg H, Rosen JC, Wolf J, Vara LS, Detzer MJ, Srebnik D. Comparison of cognitive-behavior therapy and desipramine in the treatment of bulimia nervosa. Behav Res Ther 1994;32:37-45.
63 Cooper PJ, Coker S, Fleming C. Self-help for bulimia nervosa: a preliminary report. Int J Eat Disord 1994:16:401-4.
64 Goldbloom DS, Olmsted MP, Davis R, Clewes J, Heinmaa M, Rockert W, et al. A randomized controlled trial of fluoxetine and cognitive-behavioral therapy for bulimia nervosa: a short-term outcome. Behav Res Ther 1997;35:803-11.
65 Walsh BT, Wilson GT, Loeb KL, Devlin MJ, Pike KM, Roose SP, et al. Medication and psychotherapy in the treatment of bulimia nervosa. Am J Psychiatry 1997;154:523-31.
66 Fassino S, Abbate Daga G, Piero A, Leombruni P, Rovera GG. Dropout from Brief Psychotherapy within a Combination Treatment in Bulimia nervosa: Role of Personality and Anger. Psychoter Psychosom 2003;4:203-10
67 McCann UD, Agras WS. Successful treatment of nonpurging bulimia nervosa with desipramine: a double-blind, placebo-controlled study. Am J Psychiatry 1990;147:1509-13.
68 Marcus MD, Wing RR, Ewing L, Kern E, McDermott M, Gooding W. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge eaters and non-binge eaters. Am J Psychiatry 1990;147:876-81.
69 Greeno CG, Wing RR. A double-blind, placebo-controlled trial of the effect of fluoxetine on dietary intake in overweight women with and without binge-eating disorder. Am J Clin Nutr 1996;64:267-71.
70 Arnold LM, McElroy SL, Hudson JI, Welge JA, Bennett AJ, Keck PE. A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. J Clin Psychiatry 2002;11:1028-33.
71 Hudson JI, McElroy SL, Raymond N, Crow SJ, Keck PE, Jr., Carter WP, et al. Fluovoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry 1998;155:1756-62.
72 McElroy SL, Casuto LS, Nelson EB, Lake KA, Soutullo CA, Keck PE Jr, et al. Placebo-controlled trial of sertraline in the treatment of binge-eating disorder. Am J Psychiatry 2000;157:1004-6.
73 Ricca V, Mannucci E, Mezzani C, Moretti S, Di Bernardo M, Bertelli M, et al. Fluoxetine and fluovoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study. Psychother Psychosom 2001;70:298-306.
74 Malhotra S, King KH, Welge, JA, Brusman-Lovins L, McElroy SL. Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients. J Clin Psychiatry 2002;9:802-6.
75 Shapira NA, Goldsmith TD, McElroy SL. Treatment of binge-eating disorder with topiramate: a clinical case series. J Clin Psychiatry 2000;61:368-72.
76 Appolinario JC, Coutinho W, Fontenelle L. Topiramate for binge-eating disorder (letter). Am J Psychiatry 2001;158:967-8.
77 Appolinario JC, Fontenelle LF, Papelbaum M, Bueno JR, Coutinho W. Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry 2002;47:271-3.
78 Stunkard A, Berkowitz R, Tanrikut C, Reiss E, Young L. d-Fenfluramine treatment of binge eating disorder. Am J Psychiatry 1996;153:1455-9.
79 Alger SA, Malone M, Cerulli J, Fein S, Howard L. Beneficial effects of pharmacotherapy on weight loss, depressive symptoms, and eating patterns in obese binge eaters and non-binge eaters. Obes Res 1999;7:469-76.
80 Appolinario JC, Godoy-Matos A, Fontenelle LF, Carraro L, Cabral M, Vieira A, et al. An open trial of sibutramine in obese patients with binge eating disorder. J Clin Psychiatry 2002;1:28-30.
81 Marcus MD, Wing RR, Ewing L, Kern E, Gooding W, McDermott M. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge eaters and non-binge eaters. Am J Psychiatry 1990;147:876-81.
82 Agras WS, Telch CF, Arnow B, Eldredge K, Wilfley DE, Raeburn SD, et al. Weight loss, cognitive-behavioral, and desipramine treatments in binge eating disorder. An additive design. Behav Ther 1994;25:225-38.
83 Devlin MJ, Goldfein JA, Carino JS, Wolk SL. Open treatment of overweight binge eaters with phentermine and fluoxetine as an adjunct to cognitive-behavioral therapy. Int J Eat Disord 2000;28:325-32.
84 Laederach-Hofmann K, Graf C, Horber F, Lippuner K, Lederer S, Michel R, et al. Imipramine and diet counselling with psychological support in the treatment of obese binge eaters: a randomized, placebo-controlled double-blind study. Int J Eat Disord 1999;2:31-44.